A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3

Clinical Cancer Research

Volumn 17, Issue 22, 2011, Pages 7127-7138

  Liu, Xiangdong ^a   Wang, Qian ^a   Yang, Gengjie ^a   Marando, Cindy ^a   Koblish, Holly K ^a   Hall, Leslie M ^a   Fridman, Jordan S ^a   Behshad, Elham ^a   Wynn, Richard ^a   Li, Yu ^a   Boer, Jason ^a   Diamond, Sharon ^a   He, Chunhong ^a   Xu, Meizhong ^a   Zhuo, Jincong ^a   Yao, Wenqing ^a   Newton, Robert C ^a   Scherle, Peggy A ^a  

^a Experimental Station   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; INCB 28060; PROTEIN HER 3; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SPECIFICITY; ENZYME ACTIVATION; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; MIGRATION INHIBITION; MITOSIS INHIBITION; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FEMALE; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 81255138189     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1157     Document Type: Article

References (36)

1. Birchmeier C, Birchmeier B, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-25. (Pubitemid 37493640)
2. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005;225:1-26. (Pubitemid 40732764)
3. Roos F, Ryan AM, Chamow SM, Bennett GL, Schwall RH. Induction of liver growth in normal mice by infusion of hepatocyte growth factor/scatter factor. Am J Physiol 1995;268:G380-6.
4. Michalopoulos GK, DeFrances MC. Liver regeneration. Science 1997;276:60-6.
5. Matsumoto K, Nakamura T. Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. Kidney Int 2001;59: 2023-38. (Pubitemid 32467594)
6. Nakamura T, Mizuno S, Matsumoto K, Sawa Y, Matsuda H, Nakamura T. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest 2000;106:1511-9. (Pubitemid 32038589)
7. Rabkin R, Fervenza F, Tsao T, Sibley R, Friedlaender M, Hsu F, et al. Hepatocyte growth factor receptor in acute tubular necrosis. J Am Soc Nephrol 2001;12:531-40. (Pubitemid 32180022)
8. Van Andel Institute. Hepatocyte growth factor/scatter factor, Met and cancer references [database on the Internet]. Grand Rapids (MI): Van Andel Institute. Available from: http://www.vai.org/met/.
9. Schmidt L, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller M, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999;18:2343-50. (Pubitemid 29192711)
10. Liu X, Yao W, Newton RC, Scherle PA. Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Invest Drugs 2008;17:999-1011.
11. Zeng ZS, Weiser MR, Kuntz E, Chen CT, Khan SA, Forslund A, et al. c-MET gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett 2008;265:258-69.
12. Galeazzi E, Olivero M, Gervasio FC, De Stefani A, Valente G, Comoglio PM, et al. Detection of MET oncogene/hepatocyte growth factor receptor in lymph node metastases from head and neck squamous cell carcinomas. Eur Arch Otorhinolaryngol 1997;254 Suppl 1: S138-43. (Pubitemid 27110381)
13. Graveel C, Su Y, Koeman J, Wang LM, Tessarollo L, Fiscella M, et al. Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. Proc Natl Acad Sci U S A 2004;101:17198-203. (Pubitemid 39627797)
14. Ponzo MG, Lesurf R, Petkiewicz S, O'Malley FP, Pinnaduwage D, Andrulis IL, et al. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci U S A 2009;106:12903-8.
15. Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 2009;69:3021-31.
16. Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT, et al. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res 2009;15:3740-50.
17. Okuda K, Sasaki H, Yukiue H, Yano M, Fujii Y. Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci 2008;99:2280-5.
18. Toiyama Y, Miki C, Inoue Y, Okugawa Y, Tanaka K, Kusunoki M, et al. Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients. Int J Cancer 2009;125:1657-62. (Pubitemid 44441370)
19. Gupta A, Karakiewicz PI, Roehrborn CG, Lotan Y, Zlotta AR, Shariat SF, et al. Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer. Clin Cancer Res 2008;14:7385-90.
20. Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small cell lung cancer patients. J Clin Oncol 2009;27:1667-74.
21. Kammula US, Kuntz EJ, Francone TD, Zeng Z, Shia J, Landmann RG, et al. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett 2007;248:219-28. (Pubitemid 46330555)
22. Weng L, Qiao L, Zhou J, Liu P, Pan Y, inventors; Incyte Corporation, assignee. Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b] [1,2,4]triazin-2-yl]benzamide and processes related to preparing the same. Europe patent WO 2009143211. 2009 Nov 26.
23. Behshad E, Klabe RM, Margulis A, Becker-Pasha M, Rupar MJ, Collier P, et al. Phosphorylation state-dependent high throughput screening of the c-MET kinase. Curr Chem Genomics 2010;4:27-33.
24. Liu X, Fridman JS, Wang Q, Caulder E, Yang G, Covington M, et al. Selective inhibition of ADAM metalloproteases blocks HER-2 extra-cellular domain (ECD) cleavage and potentiates the anti-tumor effect of trastuzumab. Cancer Bio Ther 2006;5:648-56. (Pubitemid 44024720)
25. Kong-Beltran K, Seshagiri S, Zha J, Zhu W, Bhawe K, Mendoza N, et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 2006;66:283-9. (Pubitemid 43166034)
26. Rong S, Bodescot M, Blair D, Dunn J, Nakamura T, Mizuno K, et al. Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol Cell Biol 1992;12:5152-8.
27. Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, et al. An orally available small-molecule inhibitor of c-MET, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007;67:4408-17. (Pubitemid 46815090)
28. Reznik TE, Sang Y, Ma Y, Abounader R, Rosen EM, Xia S, et al. Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor. Mol Cancer Res 2008;6: 139-50. (Pubitemid 351378174)
29. Liu X, Newton RC, Scherle PA. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med 2010;16:37-45.
30. th Congress of the European Society for Medical Oncology; 2010. Abstract number 5146.
31. Mekhail T, Rich T, Rosen L, Chai F, Semic-Suka Z, Savage RE, et al. Final results: a dose escalation phase I study of ARQ197, a selective c-Met inhibitor, in patients with metastatic solid tumors. J Clin Oncol 27:15s, 2009; (suppl; abstr 3548).
32. Eder JP, Shapiro GI, Appleman LJ, Zhu AX, Miles D, Keer H, et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res 2010;16:3507-16.
33. Kurzrock R, ShermanS,HongD,NgC, Frye J, Janisch L, et al.Aphase I study of XL184, a MET, VEGFRs, and RET kinase inhibitor, administered orally to patients (pts) with advanced malignancies, including a subgroup of pts with medullary thyroid cancer (MTC) [abstract]. In: The AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics, Discovery, Biology, and Clinical Applications. 2008 Oct 21-24; Geneva, Switzerland. Philadelphia (PA): AACR; 2008. Abstract nr 379.
34. Gordon MS, Sweeney CS, Mendelson DS, Eckhardt SG, Anderson A, Beaupre DM, et al. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res 2010;16: 699-710.
35. Munshi N, Jeay S, Li Y, Chen CR, France DS, Ashwell MA, et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 2010;9: 1544-53.
36. Clinicaltrials.gov. A phase I, open-label, dose-escalation study to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of INCB028060 in subjects with advanced malignancies. Bethesda, MD: NIH. Available from: http://clinicaltrials.gov/ct2/results?term=INCB028060.